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BACKGROUND

DISCUSSION

• Prior to the introduction of the highly active antiretroviral therapy (HAART) in
1996, Kaposi Sarcoma (KS) was the most common neoplasm in patients with
HIV, and an important cause of morbidity and mortality in AIDS.1 The
incidence of KS and AIDS-defining malignancies have decreased significantly in
the era of HAART.2

• KS is a low-grade vascular tumor associated with human
herpesvirus-8 (HHV-8). Studies have shown that environmental
stressors such as hypoxia, and poor T-cell immunity can stimulate
its proliferative potential and promote oncogenesis activity. 3

• Clinicians unfamiliar with KS and its complications may experience delays in
diagnosis and treatment.

• Patients with HIV have a significantly increased risk of malignancies
including KS due to immunosuppression. Since the introduction of
HAART in 1996, the incidence of AIDS-defining cancers has
significantly declined.4

CASE PRESENTATION
Pertinent Past Medical History
• A 59-year-old Caucasian male with a 20-year history of HIV and a history of
biopsy-proven skin KS 15 years prior to admission.
• During period of consistent HAART use, from 2006-12, HIV was suppressed
(CD4>1000) and KS was in remission. He was lost to care from 2013-18.

Image 1: On right leg and dorsum of the right foot, multiple poorly demarcated coalescing purple
papules and plaques with thick scale present. On right plantar foot, poorly demarcated purple-todeep black thin papules, coalescing into plaques. Dystrophic, necrotic-appearing toenails present.

• The control of KS is directly related to Low CD4 count and viral load.
This patient has had a long history of HIV with significant
interruptions of care and HAART, which were a major reason for KS
progression and visceral spread of the malignancy.2

• He was admitted to outside hospital in April 2018 with dyspnea. Pneumocystis
jiroveci pneumonia (PJP) was positive in bronchoalveolar lavage (BAL) per
nucleic acid amplification test (NAAT), CD4=5, and HIV viral load > 6 log.

• Prevention of AIDS-defining cancers and other sequelae of HIV is
best achieved by immediate and uninterrupted HAART.4, 5, 6

• He initially responded in hospital to TMP/SMX and was discharged on 4 L
oxygen, and to complete TMP/SMX course. He was referred back to ID clinic
when he was prescribed HAART which he never re-started.

• Despite the decline in KS in recent years with the era of HAART, its
pulmonary manifestations have been linked to interruption or lack
of HIV care.7

Hospital Course
• Chief complaint: He presented to ASLMC with worsening dyspnea, and dry
cough.
• Vitals: T 97.8oF , BP 118/60 , HR 78 , RR 25 , POx 91% on 6L of oxygen.
• Physical Exam: Cachectic male in respiratory distress, scattered wheezing
bilaterally, and right leg skin lesions suggestive of KS (image 1).

Image 2: CXR shows extensive bilateral infiltrations.
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• Imaging: CXR reveals extensive bilateral pulmonary infiltrates (image 2).
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• Initial management: Re-started on TMP/SMX, and prednisone. HAART was
initiated. Shortly after admission to medical floor, he developed severe
hypoxic respiratory failure necessitating ICU transfer and eventual intubation.
• Further evaluation: Bronchoscopy revealed normal airway anatomy and
appearance. BAL negative for PJP per direct fluorescent antibody (DFA). A
random transbronchial biopsy was suggestive of KS (image 3).

Patient Outcome
• Hematology/Oncology was consulted, and one dose of liposomal doxorubicin
was administered.
• The patient continued to have refractory hypoxia despite being maximized on
the ventilator. He was made comfort care by family given the poor prognosis.

• Pulmonary KS should be considered promptly in patients with
dyspnea or pleural effusion in all patients with a history of KS,
especially when the CD4 count is low and/or there is a history of
interruptions of HAART.

Image 3: Transbronchial biopsy reveals fragments of alveolar parenchyma and bronchial mucosa
containing spindle cell proliferation in the H/E stain (left). Immunostaining for HHV-8 is positive (right).
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